Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.56, $0.03 better than the analyst estimate of $0.53. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.72 billion.

GUIDANCE:

Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus of $2.27. Teva Pharma sees FY2023 revenue of $15-15.4 billion, versus the consensus of $15.02 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.